Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne Mea Spanjaart, Per Ljungman, Rafael de La Camara, Gloria Tridello, Valentín Ortiz-Maldonado, Alvaro Urbano-Ispizua, Pere Barba, Mi Kwon, Dolores Caballero, Pierre Sesques, Emmanuel Bachy, Roberta Di Blasi, Catherine Thieblemont, Friso Calkoen, Pim Mutsaers, Johan Maertens, Livia Giannoni, Emma Nicholson, Matthew Collin, Carlos Pinho VazElisabetta Metafuni, Joaquin Martinez-Lopez, Fiona L. Dignan, Josep Maria Ribera, Arnon Nagler, Frantisek Folber, Robin Sanderson, Adrian Bloor, Fabio Ciceri, Nina Knelange, Francis Ayuk, Nicolaus Kroger, Marie José Kersten, Stephan Mielke*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)3585-3588
Number of pages4
JournalLeukemia
Volume35
Issue number12
DOIs
StatePublished - Dec 2021

Funding

FundersFunder number
Kite/Gilead
Miltenyi Biomedicine
AMGEN
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Novartis
Roche
Gilead Sciences
Celgene
Takeda Pharmaceutical Company
Janssen Pharmaceuticals
Generalitat de CatalunyaBDNS357800
Miltenyi Biotec
Shire
Instituto de Salud Carlos III20/00197, FIS16/01433

    Cite this